Clinical outcomes after interstitial high-dose-rate brachytherapy vs. stereotactic body radiotherapy in hepatocellular carcinoma: A retrospective matched single-center analysis.

Authors

Sebastian Teich, Anna-Maria Bühler, Sebastian Schäfer, Philipp Geisler, Saskia Spautz, Isabell Prager, Stefan Dietzsch, Ilias Sachpazidis, Dimos Baltas, Christos Moustakis, Nils H Nicolay, Franziska Nägler, Kathrin Hering

Published in

Journal of contemporary brachytherapy. Volume 18. Issue 3. Pages 236-247. Epub Aug 24, 2026.

Abstract

Interstitial high-dose-rate brachytherapy (iBT) and stereotactic body radiotherapy (SBRT) are local treatment options for hepatocellular carcinoma (HCC). Data comparing their efficiency and safety profile remain limited. Therefore, we aimed to compare treatment results of iBT and SBRT in HCC patients.
Patients with HCC who underwent iBT or SBRT between 2014 and 2024 at our tertiary center were retrospectively analyzed. Local control (LC), progression-free survival (PFS), and overall survival (OS) were evaluated. Treatment-related acute and chronic toxicities were assessed.
In a cohort of 92 patients with 125 HCC lesions, 60 patients (65.2%) with 86 lesions (68.8%) were treated with iBT. The median follow-up was 21 months. There were no significant differences in LC (p = 0.73) or PFS (p = 0.27) between iBT and SBRT cohorts. To reduce confounding due to imbalances in baseline characteristics, a 1 : 1 matched sub-cohort was generated. For all patients with complete clinical data, each SBRT patient was matched to one iBT patient using a multivariable distance metric based on Charlson comorbidity index (CCI), liver cirrhosis, Child-Pugh score (CPS), albumin-bilirubin (ALBI) score, and age, resulting in two equally-sized groups with reduced baseline imbalance. After matching, the OS advantage of iBT over SBRT was no longer statistically significant. The most common acute treatment-related toxicities were grade 1 elevations of liver enzymes in the iBT group (12/60, 20%) and fatigue in the SBRT group (5/32, 15.6%). In the iBT group, two minor bleeding events and one pneumothorax occurred, but no grade > 3 late toxicity was observed.
Both iBT and SBRT provide effective local treatment options for HCC, achieving comparable LC and PFS, while maintaining a manageable toxicity profile. Patient selection should be guided by institutional expertise and patient preference.

PMID:
42877548
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.